StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research note released on Monday morning. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reiterated a buy rating and issued a $4.25 price target on shares of OncoCyte in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, OncoCyte currently has a consensus rating of Hold and a consensus target price of $4.06.

OncoCyte Stock Performance

Shares of OncoCyte stock opened at $3.10 on Monday. The firm’s 50-day simple moving average is $3.13 and its 200-day simple moving average is $2.93. OncoCyte has a twelve month low of $2.08 and a twelve month high of $4.34.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The business had revenue of $0.10 million for the quarter. On average, equities analysts forecast that OncoCyte will post -2.58 earnings per share for the current fiscal year.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.